The durable remission of B-cell leukemia and lymphoma following chimeric antigen receptor (CAR) T-cell therapy has brought this new form of adoptive immunotherapy to center stage with the expectation that CAR T-cell therapy may provide similar efficacy in other hematologic and solid cancers. Herein, we review recent advances in the areas of CAR design that improve CAR T-cell proliferation, engraftment, and efficacy, as well as clinical application strategies that are designed to improve clinical efficacy while reducing the risk of toxicity and broaden patient access to this promising form of cancer immunotherapy. D.J.P.; KO8-CA166039, to M.V.M.). Conflicts of Interest and Source of Funding: M.V.M. and D.J.P. receive research funding related to CAR T-cell therapy provided through an alliance between Novartis and the University of Pennsylvania and have patent applications in some of the technology described in this article.
T he advent of advanced gene transfer and cell cultivation technologies now makes it possible to redirect the effector functions of a patient's T-cells against an antigen on the cancer cell surface via a chimeric antigen receptor (CAR), commonly composed of an extracellular antigen binding moiety (e.g., antibody scFv) fused to intracellular signaling domains for T-cell activation. Adoptive transfer of CAR T-cells redirected against CD19 can result in durable, complete remission of B-cell lymphomas and leukemias, including a nearly 90% response rate in acute lymphoid leukemia. 1 Still, toxicities such as cytokine release syndrome and occasional neurotoxicities do occur, and similar success in solid tumors still remains elusive, given the immunosuppressive tumor microenvironment (TME) and difficulties in identifying sound target antigens that are not also expressed on normal tissues. Indeed, on-target, off-tumor toxicities have been noted in some CAR T-cell therapy trials 2, 3 ; however, advances in gene transfer platforms, CAR design, and clinical strategies that potentiate and focus antitumor activity while sensitizing the tumor cells and its associated microenvironment to CAR T-cell attack now provide an opportunity to safely and effectively treat these cancers.
Several outstanding questions in the field of CAR T-cell therapy exist; among these are what defines a potent cell product, what factors are most important to achieve engraftment and expansion of a cell product, and what factors are most responsible for achieving a durable antitumor response. It is becoming increasingly clear that T-cell engraftment and persistence are the keys to antitumor efficacy. 4 The field has therefore concentrated on 3 complementary approaches to improve efficacy: (1) facilitating in vivo expansion and engraftment by either increasing cell quality or dose or providing host conditioning, (2) genetic manipulation of T-cells to increase their proliferative capacity or become resistant to the inhibitory TME, and (3) selecting a starter T-cell population that would be predicted to have a favorable proliferative potential.
HOST AND TUMOR CONDITIONING
One way to increase the efficacy of CAR T-cell therapy is to "condition" the host with chemotherapy and/or radiation, resulting in lymphodepletion prior to administering CAR T-cells. 5 Lymphodepletion may exert its effects in 3 different ways: (1) reduction in regulatory T-cells and immunosuppressive macrophages, 6 (2) reduction in disease burden, and/or (3) facilitating homeostatic proliferation by increased availability of endogenous cytokines, including interleukin 7 (IL-7). 7 Although chemotherapy with or without radiation is a common conditioning strategy, it is relatively nonspecific. Alternative, mechanism-based conditioning regimens such as regulatory T-cells-reducing strategies with IL-2 immunotoxin (Ontak) or daclizumab (anti-CD25) could be considered. Recently, targeted small molecule drugs, such as CSF-1R and IDO inhibitors, have also been shown to affect the immunosuppressive myeloid-derived suppressor cells. 8, 9 Combinations of T-cells with a variety of other targeted drugs may have beneficial effects by sensitizing tumors to T-cell-mediated killing and may also have independent effects on T-cell biology. [10] [11] [12] Although it is fairly well established that lymphodepleting chemotherapy aids in infused T-cell engraftment, it is not clear that lymphodepletion is absolutely required for effective therapy, particularly when the T-cell product is optimally cultured and has adequate potency. Finally, the importance of lymphodepletion and the regimen used may be disease-specific and therefore bears consideration.
ENGINEERING POTENCY
Beyond host conditioning, productive CAR T-cell proliferation, effector function, and survival rely on coordinate delivery of an activation signal, often via a T-cell receptor (TCR) CD3ζ or an Fc receptor subunit, in parallel with a secondary costimulatory signal. The modular design of a CAR permits the inclusion of CD3ζ and costimulatory signaling domains in tandem for cis signaling that attempts to mimic natural costimulation in trans during TCR activation for full T-cell activation. In a competitive repopulation study by Savoldo et al, 13 first-generation CAR T cells lacking a costimulatory signaling domain did not persist, whereas second-generation CAR T-cells containing a CD28 signaling domain proliferated and persisted after coadministration, emphasizing the need for costimulation. The concept now emerges that costimulatory domain selection can influence the nature of CAR T-cell persistence and function. CD28 and 4-1BB have been most widely applied in CAR T-cell therapy, with a growing body of patient and preclinical data suggesting that CD28 signaling supports robust effector function but with coordinate exhaustion and reduced capacity to persist in vivo, compared with 4-1BB signaling that promotes T-cell survival. [14] [15] [16] [17] Accordingly, CAR T-cells may be tuned for short-term or long-lasting effects in vivo, through provision of CD28 or 4-1BB signaling, respectively. Still, CARs that include alternative costimulatory molecules from the tumor necrosis factor receptor superfamily such as CD27, 16 OX40 (CD134), or inducible costimulatory (ICOS) 18 can confer CAR T-cells with qualities that rationalize their clinical investigation. Like 4-1BB, CD27 promotes CAR T-cell resistance to antigen-induced cell death and antiapoptotic Bcl-xL up-regulation associated with enhanced survival and antitumor activity in vivo, compared with CD28. 16 In contrast, OX40 confers CAR T-cells with a capacity for antigen-stimulated proliferation and cytokine production that is superior to first-generation CARs but reduced relative to CD28. 19 Evidence that ICOS signaling promotes the development of human CD4 + T helper 17 (T H 17) cells 20 has restored interest in the use of ICOS in second-generation CARs and led to the generation of T H 17-like tumor-specific CAR T-cells capable of producing both IL-17 and interferon γ with an enhanced capacity to persist, relative to CD28 or 4-1BB containing CAR T-cells. 21 Whether and which combination of 2 or more costimulatory domains in the same CAR best enhances net CAR T-cell activity require further investigation as both additive 19, 22 and diminished benefits have been reported. 23 However, what is growing clear is that CD4 + and CD8 + CAR T-cells require distinct costimulation signals for optimal persistence and activity. Compared with CD28 and 4-1BB, ICOS-based CARs significantly increase CD4 + T-cell in vivo persistence, an effect heightened by ex vivo culturing under T H 17 conditions. 24 CD4 + ICOS-CAR T-cells also bolstered CD8 + CD28-and 4-1BBbased CAR T-cell persistence and antitumor activity when coadministered in preclinical models, lending credence to tailored CAR T-cell design and culture conditioning for various T-cell subsets prior to infusion for maximized efficacy.
Conventional CARs are designed to possess costimulatory domains in tandem with a TCR signaling domain for cis signaling; however, costimulatory signals can be disentangled from CD3ζ signaling by the creation of dual CAR T-cells that transmit signal 1 (TCR) through a first-generation CD3ζ-based CAR and signal 2 (costimulation) through a secondary CAR of distinct antigen specificity containing only a costimulatory endodomain for ligand-dependent costimulatory signaling in trans. [25] [26] [27] These dual CAR T-cells receive TCR and costimulatory signals in trans akin to natural T-cell activation and are similar in potency to standard cis-signaling CARs, but have the added benefit of achieving full activation only upon simultaneous encounter and stimulation with 2 discrete antigens on cancer cells, improving their ability to sense tumor and dampening their response to healthy tissues bearing single antigen. Trans costimulatory signaling in CAR Tcells can also be achieved through the engineered surface expression of a costimulatory ligand, such as 4-1BBL, for presumed autocrine crosslinking with its costimulatory receptor. Using this approach, CD28-based CD19-specific CAR T-cells outfitted with 4-1BBL showed the greatest persistence and mediated complete tumor eradication in a preclinical NALM-6 model, whereas standard CD28-based CD19 CAR T-cells showed reduced persistence and partial responses. 28 Using a different multichain CAR signaling approach, Wang et al 29 engineered an scFv-based CAR containing the transmembrane and cytoplasmic domains of a stimulatory killer immunoglobulin-like receptor (KIR), KIR2DS2, into human T-cells along with DAP12, an ITAM-containing adaptor, for multichain CAR signaling. T-cells expressing the KIR-CAR and DAP12 exhibited antitumor activity that was superior to second-generation CD3ζ-based CARs carrying either CD28 or 4-1BB domains in a xenograft model, which reflected a heightened potency on the per cell basis, and not increased proliferation and persistence in vivo. Accordingly, this multichain approach may provide utility in solid tumors that resist conventional CAR T-cell therapy.
Enhanced CAR T-cell potency may also be conferred by engineering cells to resist immunosuppression in the TME through the use of a dominant negative TGFb or immune potentiating "switch receptors" composed of an extracellular inhibitory receptor domain (e.g., PD-1, CTLA-4) to intracellular costimulatory domains, including CD28, which invigorate antitumor activity in response to inhibitor ligands. 30 CAR T-cells can also be engineered for inducible or constitutive activity using activating transcription factors, cytokines, or antiapoptotic molecules. CAR T-cell potency may also be limited by accessibility issues in solid tumors that may be overcome by regional cell delivery 31 or engineered chemokine receptors, for example, CCR2b, 32 for specific trafficking. The use of CAR T-cells engineered to disrupt solid tumor masses via heparinase 33 and its stroma via combination with fibroblast activation protein,, 34 prostate-specific membrane antigen, 35 or vascular endothelial growth factor receptor 36 CAR T-cells also holds promise.
OPTIMIZED T-CELL SUBSETS FOR CAR T-CELL THERAPY
Basic immunologists have uncovered different subsets of Tcells with varying degrees of proliferative capacity, effector function, and memory differentiation, many of which are characterized by the expression of specific cell-surface markers. For example, T central memory cells, characterized as CD45RO + and CCR7 + , have the capacity for long-lived persistence and retain their ability to proliferate upon antigen encounter. 37 In a nonhuman primate model, low doses of T central memory cells can engraft and establish memory, 38 and remain an area of clinical investigation. Stem cell-like memory cells are also attractive candidates for use in CAR T-cell therapy given their less differentiated phenotype, proliferative capacity, and ability to differentiate into full effectors. 39 In addition, although the ratio of CD4:CD8 T-cells in the peripheral blood of normal donors is typically 2:1, it is possible that an immunotherapeutic drug has a different optimal ratio for tissue penetration and tumor eradication. Although some investigators use bulk populations of unselected T-cells as the cell product, others use T-cell products of defined composition in terms of ratio of CD8 + central memory T-cells and CD4 T-cells. 40 Finally, resident memory T-cells that are chronically exposed to antigen, such as Epstein-Barr virus-specific or cytomegalovirus-specific Tcells, may offer some benefits, as these are naturally occurring persisting and effective T-cells in normal donors 41 and would be amenable to postinfusion antigen-specific boosting strategies.
IMPROVING CAR T-CELL SAFETY

Chimeric antigen receptor T-cells could potentially cause toxicity by any one of 3 mechanisms: (1) on-target, off-tumor effects, (2) off-target effects, or (3) activation-related cytokine production and release.
On-target, off-tumor effects are dependent on the choice of target antigen. Indeed, the most challenging roadblock to broadening the application of CAR T-cell therapies remains the selection of the target antigen. 2, 3 High-affinity CAR T-cells detect and can lyse targets expressing approximately 100 copies of the target antigen 42 ; however, affinity tuning may decrease the threshold for CAR T-cell activation, which may broaden the therapeutic window of CAR T-cells to tissues that express only high levels of antigen. 43 The ideal target antigen for a CAR T-cell is one that is expressed homogeneously on the tumor cells and has a role in maintaining tumorigenicity (to prevent antigen escape variant recurrences of tumor) and is not expressed in any essential normal tissues (to prevent toxicity). The B-cell antigen CD19 is the prototypical CAR antigen: it is expressed homogeneously in multiple tumors of B-cell origin, its expression is typically homogeneous, and it is not expressed in a life-sustaining tissue. On the contrary, its expression on normal B cells can enable isolated B-cell aplasia to serve as a biomarker of continuing CAR T-cell function. Other antigens that could fall into this category of nonessential tissue antigens include hormone receptors (thyroid stimulating, follicle stimulating, estrogen, etc.) and tissue antigens such as prostatespecific membrane or stem cell antigen. Other potential target antigens include mutated oncogenic antigens such as epidermal growth factor receptor variant III (although its expression is heterogeneous), viral antigens expressed on tumor cells such as Epstein-Barr virus or polyoma virus for lymphoma or Merkel cell cancer, tumor-specific neoantigens, and cancer testis antigens.
Off-target effects are the result of imperfect characterization of the specificity of the antigen receptor or unforeseen molecular mimicry of antigens. In this case, the engineered receptor recognizes an antigen that is similar to but was not predicted to bind to the receptor. In the case of transduced T-cells, there are limited reports of this effect, for example, where an engineered T-cell receptor specific for a cancer-testis antigen cross-reacted with a peptide from the unrelated protein Titin. 44 Off-target effects are particularly difficult to predict from preclinical studies, given that animal models by definition do not express the same antigenic repertoire as humans. Toxicity from off-target effects may be controlled by ablating or silencing the CAR T-cells.
Activation-related cytokine production or release is an expected event resulting from effective antigen encounter by CAR T-cells. Activated T-cells produce and release interferon γ, IL-2, and various other cytokines, which may in turn activate other immune cells, including macrophages. Cytokine release syndrome can be severe 45 and can be managed clinically with anticytokine therapy and/or corticosteroids. One of the advantages of anticytokine therapy is that it directly targets the secondary mediator of toxicity without necessarily impacting the T-cell engraftment, 14 and it generally has a rapid onset of action. However, abrogating the cytokine release syndrome may not have an impact on on-target or off-target toxicity, and it may be difficult to clinically distinguish these forms of toxicity in a first-in-human study of a novel CAR T-cell product.
To manage potential toxicity or to eliminate CAR T-cells after a sustained engraftment and eradication of disease, many investigators are developing "suicide genes" to incorporate into CAR T-cells. Candidate genes such as nucleoside kinases, including viral thymidine kinase or a mutated version of human thymidylate kinase, can be inactivated with nucleoside analog drugs, thereby inhibiting DNA synthesis and proliferation of the transduced cells. The main advantage of herpes simplex virusthymidine kinase as a safety switch is the ready availability and specificity of the inhibitor drug, ganciclovir 46 ; however, introduction of a viral transgene also increases the risk of immunogenicity of the CAR T-cells. Furthermore, elimination of the transduced Tcells may take several days, which may not be acceptable in the face of immediately life-threatening toxicity. Human inducible caspase 9 is a fusion protein of caspase 9 and a drug-sensitive dimerizing domain of FK506. Upon binding to the drug, the fusion protein dimerizes and initiates apoptosis in the iCaspase9transduced T-cell. The advantages of this system are that (1) it is based on human sequences; (2) the transduced cells are eliminated rapidly because no DNA synthesis is required; and (3) it has been shown to be safe and rapidly effective in an allogeneic stem cell transplant study. 47 The main disadvantage of this system is the availability of the dimerizing drug. Alternative safety switches are based on expression of a well-characterized, targetable surface antigen on the transduced T-cells, such as CD20 or variants of CD20, 48 or truncated epidermal growth factor receptor 49 ; in case of severe uncontrolled toxicity, an infusion of rituximab or cetuximab, respectively, would theoretically target the transduced T-cells for elimination. The advantages of this system are its lack of immunogenicity, the ready availability and safety of the antibodies that could be used to trigger CAR T-cell elimination, and the dual-purpose nature of the additional transgene (which can also be used to measure the persistence of the transduced T-cells). To our knowledge, these systems have not yet been tested clinically to determine their efficacy and kinetics as a CAR T-cell elimination system in the setting of clinical toxicity (Table 1) .
Directing CAR T-cell attack to tumor sites anatomically may also limit toxicity and improve efficacy. This may be achieved via intratumoral or local intralymphatic delivery or by engineering CAR T-cells to express specific chemokine receptors for trafficking to tumor. 32 Cloaking the target on normal tissue with antigen-specific antibody may effectively reduce toxicity but limits response to therapy. 2 Newer strategies now make it possible to genetically engineer CAR T-cells for conditional attack of cancer and relative sparing of normal tissue. Some of these approaches include dual trans-signaling CAR T-cells, [25] [26] [27] as well as inhibitor CARs contained for restricted functionality upon encounter of specific antigen on the normal cells, but not tumor. 50 Alternatively, one might engineer T-cells for conditional expression of the CAR using conditionally inducible promoters that are active only in the TME.
BROADENING PATIENT ACCESS THROUGH UNIVERSAL APPROACHES
Strategies are being devised to make CAR T-cell therapy universal in application through the generation of (1) so-called universal T-cells and (2) universal immune receptors. Generation of universal effector cells could provide a route for therapy in patients with autologous T-cells of poor quality or quantity and streamline commercialization of a standardized CAR T-cell product. Some approaches include the use of immortalized natural killer cell lines (e.g., NK92) or allogeneic T-cell products such as allo-depleted T-cells, allogeneic T-cells with restricted specificity (e.g., virus-specific T-cells), NKT cells, or γ-δ T-cells. The advent of genome-editing technologies now makes it possible to ablate endogenous TCR and MHC genes from allogeneic donor T-cells to create universal CAR T-cells with reduced risk of graft versus host disease and host-mediated response against the transferred product. 51 Universal immune receptors contain an extracellular moiety that serves as a scaffold for the binding of intermediate tumortargeting molecules (e.g., tagged antibodies) so that the universal receptor can be "armed" for antigen specificity or directed against a targeting molecule "painted" on the tumor cell surface. Accordingly, universal immune receptors serve as a standardized platform for adaptable redirected T-cell specificity for the targeting of multiple and diverse antigens either simultaneously or sequentially. 52 Various approaches have now been described including those that rely on biotin-avidin, antibody-Fc receptor, antibodyantigen, and metabolite-receptor interactions and are at the early phase of clinical investigation.
CONCLUSION
Chimeric antigen receptor T-cells are a nascent form of immunotherapy with tremendous potential for inducing durable antitumor effects. Numerous investigative avenues to explore range from clinical manipulations, such as combinations of drugs administered to the patient host, to genetic engineering strategies to manipulate the T-cell product, all of which have the potential to increase the safety, potency, and broad applicability of CAR T-cell technology to better the lives of patients with cancer.
